From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
C Albertini, A Salerno… - Medicinal Research …, 2021 - Wiley Online Library
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …
From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology.
C Albertini, A Salerno… - Medicinal Research …, 2020 - europepmc.org
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm" one-drug, one …
Alzheimer's disease (AD), has raised questions about the classical paradigm" one-drug, one …
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
C Albertini, A Salerno, PSM Pinheiro… - Medicinal Research …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The continued drug discovery failures in
complex neurodegenerative diseases, including Alzheimer's disease (AD), has raised …
complex neurodegenerative diseases, including Alzheimer's disease (AD), has raised …
From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology
C Albertini, A Salerno… - Medicinal research …, 2021 - pubmed.ncbi.nlm.nih.gov
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm" one-drug, one …
Alzheimer's disease (AD), has raised questions about the classical paradigm" one-drug, one …
[PDF][PDF] From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
C Albertini, A Salerno… - Medicinal Research …, 2021 - drive.google.com
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology.
C Albertini, A Salerno… - Medicinal Research …, 2021 - search.ebscohost.com
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm" one‐drug …
Alzheimer's disease (AD), has raised questions about the classical paradigm" one‐drug …
From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology
C Albertini, A Salerno… - MEDICINAL …, 2021 - cris.unibo.it
The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one-drug, one …
Alzheimer's disease (AD), has raised questions about the classical paradigm “one-drug, one …